AstraZeneca PLC (AZN)
77.62
-0.56
(-0.72%)
USD |
NASDAQ |
Sep 27, 16:00
77.62
0.00 (0.00%)
After-Hours: 20:00
AstraZeneca Research and Development Expense (Annual): 10.94B for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 10.94B |
| December 31, 2022 | 9.762B |
| December 31, 2021 | 9.736B |
| December 31, 2020 | 5.991B |
| December 31, 2019 | 6.059B |
| December 31, 2018 | 5.932B |
| December 31, 2017 | 5.757B |
| December 31, 2016 | 5.89B |
| December 31, 2015 | 5.997B |
| December 31, 2014 | 5.579B |
| December 31, 2013 | 4.821B |
| December 31, 2012 | 5.243B |
| December 31, 2011 | 5.523B |
| December 31, 2010 | 5.318B |
| December 31, 2009 | 4.409B |
| December 31, 2008 | 5.179B |
| December 31, 2007 | 5.162B |
| Date | Value |
|---|---|
| December 31, 2006 | 3.902B |
| December 31, 2005 | 3.379B |
| December 31, 2004 | 3.467B |
| December 31, 2003 | 3.012B |
| December 31, 2002 | 3.069B |
| December 31, 2001 | 2.687B |
| December 31, 2000 | 2.895B |
| December 31, 1999 | 2.472B |
| December 31, 1998 | 2.103B |
| December 31, 1997 | 1.079B |
| December 31, 1996 | 1.031B |
| December 31, 1995 | 848.32M |
| December 31, 1994 | 809.84M |
| December 31, 1993 | 767.71M |
| December 31, 1992 | 676.44M |
| December 31, 1991 | 703.57M |
| December 31, 1990 | 704.06M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
5.991B
Minimum
2020
10.94B
Maximum
2023
8.497B
Average
9.736B
Median
2021
Research and Development Expense (Annual) Benchmarks
| Amgen Inc | 4.784B |
| Johnson & Johnson | 15.08B |
| Eli Lilly and Co | 9.313B |
| Novo Nordisk AS | 4.710B |
| Sanofi SA | 7.284B |